bioAffinity Technologies, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Health Care Patient Service at $5.0 million, 81% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
|---|---|---|---|---|---|
| Revenue |
6
|
6
|
9
|
3
|
0
|
| Health Care Patient Service |
—
|
5
-39.2%
share 80.7%
|
8
+271.7%
share 87.3%
|
2
share 86.9%
|
—
|
| Histology Service Fees |
—
|
1
+1.2%
share 18.1%
|
1
+304.8%
share 11.8%
|
0
share 10.8%
|
—
|
| Medical Director Fees |
—
|
0
+2.5%
share 1.1%
|
0
+244.5%
share 0.7%
|
0
share 0.8%
|
—
|
| Department Of Defense Observational Studies |
—
|
0
-93.3%
share 0.0%
|
0
-55.5%
share 0.1%
|
0
share 0.8%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.